Investment
Features
FeesSafety
Academy
More
Pluang+

Nasdaq hits record high as AI tech and software deals drive growth despite rising Treasury yields.

Market News
05 Oct 2026
FXEmpire
View Source
Bullish
Nasdaq hits record high as AI tech and software deals drive growth despite rising Treasury yields.

The Nasdaq Composite reached a new record high, fueled by strong interest in AI-related tech stocks and major software acquisitions like PTC's $22.6 billion buyout by Schneider Electric. Despite rising long-term Treasury yields, investors continue to favor growth stocks, especially those linked to AI software, security, and computing. Other indexes like the Dow and S&P 500 also rose, supported by upgrades and deals in various sectors. The market remains cautious about bond yields, but tech's momentum and strategic acquisitions keep driving gains.

The Nasdaq Composite's record high is notable alongside Pluang's Technology sector data as of Oct 06, 2026 01:21 WIB. Among 150 priced US tech stocks on Pluang, 87 rose and 63 fell. Key movers include VNET at USD 5.44 (+6.04%), Applovin Corporation at USD 284.41 (+6.04%), and Unity Software Inc at USD 46.00 (+5.48%), with typical hold times ranging from 15 to 50 days and varied Pluang order activity percentages.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
1 hour ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
2 hours ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
3 hours ago
Near Protocol (NEAR) jumps nearly 6% amid $280K short liquidations on major exchanges

Near Protocol (NEAR) jumps nearly 6% amid $280K short liquidations on major exchanges

Near Protocol (NEAR) surged to $5.28, rising 5.94% within four hours on October 6, driven by $280,000 worth of short position liquidations across Binance, Bybit, and OKX. The price climbed from $4.98 during this period and showed a 7.14% gain over th...

Market News
Bullish
4 hours ago
Class action lawsuit filed against Alphabet over misleading statements on Gemini 3.5 Pro delays

Class action lawsuit filed against Alphabet over misleading statements on Gemini 3.5 Pro delays

A class action lawsuit has been filed against Alphabet Inc. for allegedly making false and misleading statements about the performance and launch delays of its Gemini 3.5 Pro product between May 19 and July 16, 2026. The lawsuit claims these misstate...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App